Nuvalent, Inc.'s New Drug Application (NDA) was accepted by the FDA for Priority Review.
4 reports, 1 independent
Updated May 27
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Nuvalent, Inc.'s New Drug Application (NDA) was accepted by the FDA for Priority Review.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Nuvalent's NDA was accepted by the FDA for Priority Review.1 source
- Nuvalent aligned with FDA on NDA submission strategy.
- Nuvalent is seeking FDA approval for its cancer drug while market analysts and competitors monitor the progress.
Keep exploring
The entities involved
- FDA
-
Nuvalent, Inc. (United States)
company in Cambridge, United States
Nothing else this week.
Related events
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
- Teva Pharmaceutical Industries Ltd. submitted an NDA for ecopipam to the FDA.
- A supply deal for NUBEQA was finalized between ORIC Pharmaceuticals and BAYER after talks with the FDA.
- BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
Coverage
Newest first; wire copies grouped- prnewswire.com
- Unknown outlet
- Unknown outlet
- Unknown outlet